This raises hope that pharmacodynamics stratification tool such as DR_MOMP may not only identify patients responding to BCL(X)L inhibition, but may also be able to define those that may benefit from low concentrations of BCL(X)L selective inhibitors, thereby reducing unwanted side effects such as thrombocytopenia. Here, BCL2L1 is linked to Thrombocytopenia.